Potassium Chloride
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
methscopolamine
Quaternary amine, muscarinic antagonist · Anticholinergic
Quaternary amine, muscarinic antagonistAnticholinergicATC A03AB01
CDSCO approvedATC A03AB01
EXCRETION
—
not curated
INTERACTIONS
4 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- Potassium ChlorideSevereDatabaseDDInter
- Potassium CitrateSevereDatabaseDDInter
- TopiramateSevereDatabaseDDInter
- ZonisamideSevereDatabaseDDInter
Mechanism
Quaternary ammonium derivative of scopolamine, therefore lacks the central actions of scopolamine because it does not cross the blood-brain barrier.
Indications
Temporary relief of symptoms of allergic rhinitisSinusitisCommon coldPeptic ulcer disease (formerly)IBS (off-label use, to prevent pain and fecal urgency)
Dosing
- Adult
- 2.5 mg a half hour before meals and 2.5 to 5 mg at bedtime.
Contraindications
- Colitis
- Reflux esophagitis
- Bowel obstruction
Side effects
Common
DizzinessDry mouthNauseaBlurred vision
Drug interactions
Potassium Citrate
Severe
Database
Clinical effect not specified
Source: DDInter
Topiramate
Severe
Database
Clinical effect not specified
Source: DDInter
Zonisamide
Severe
Database
Clinical effect not specified
Source: DDInter
8 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Preventive care in inflammatory bowel disease
ACG · Gastroenterology · 2025
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Cardiovascular disease prevention
ESC · Cardiology · 2021
Primary prevention of cardiovascular disease
AHA · Cardiology · 2019
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Other Quaternary amine, muscarinic antagonist drugs
Ask House about methscopolamine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team